NEW YORK, NY / ACCESSWIRE / January 13, 2015 / Market Exclusive announces that H.C. Wainwright & Co has raised its 12-month price target for Advaxis, Inc. (Nasdaq: ADXS) to $14.00 per diluted share from $8.00.
Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that is being investigated for redirecting the immune system to kill cancer.
About Market Exclusive
Market Exclusive is a financial portal geared to engaging discussion on current financial topics. Market Exclusive is not an investment advisor.
The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
SOURCE: Market Exclusive